Literature DB >> 16530300

Efficacy of inactivated trivalent influenza vaccine in alleviating the febrile illness of culture-confirmed influenza in children in the 2000-2001 influenza season.

Makoto Kamada1, Takao Nagai, Takuji Kumagai, Masahiro Igarashi, Toshiaki Ihara, Teruo Okafuji, Hitoshi Ochiai, Hiroshi Sakiyama, Kunihisa Shimomura, Eitaro Suzuki, Sadayoshi Torigoe, Chiaki Miyazaki, Akiko Miyata, Kenji Yuri, Yuhei Ito, Tetsuo Nakayama, Tetsuo Kase, Yoshinobu Okuno.   

Abstract

During the 2000/2001 influenza season in Japan, children ranging in age from 6 months to 13 years with fever exceeding 37.5 degrees C were recruited. Vaccine efficacy was evaluated by comparing the rates of pre-seasonal vaccination between groups stratified by fever severity. Seven hundred and sixty one patients (33.1%), culture positive for influenza were enrolled for analysis. The numbers of patients for A/H1N1 and A/H3N2 were insufficient for statistical analysis. For influenza B the odds ratio for vaccinated children to have a maximum fever exceeding 39.5 degrees C was 0.52 (95% CI, 0.30-0.92) Our findings suggest modest impact of influenza vaccination on limiting severity of disease symptoms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530300     DOI: 10.1016/j.vaccine.2006.01.067

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects.

Authors:  Stan L Block; Keith S Reisinger; Micki Hultquist; Robert E Walker
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

2.  Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques.

Authors:  Brendon Y Chua; Toshiki Sekiya; Marios Koutsakos; Naoki Nomura; Louise C Rowntree; Thi H O Nguyen; Hayley A McQuilten; Marumi Ohno; Yuki Ohara; Tomohiro Nishimura; Masafumi Endo; Yasushi Itoh; Jennifer R Habel; Kevin J Selva; Adam K Wheatley; Bruce D Wines; P Mark Hogarth; Stephen J Kent; Amy W Chung; David C Jackson; Lorena E Brown; Masashi Shingai; Katherine Kedzierska; Hiroshi Kida
Journal:  PLoS Pathog       Date:  2022-10-07       Impact factor: 7.464

3.  Characteristics of vaccine failures in a randomized placebo-controlled trial of inactivated influenza vaccine in children.

Authors:  Sophia Ng; Michael Y Ni; Vicky Jing Fang; Dennis Kai Ming Ip; Kwok-Hung Chan; Gabriel Matthew Leung; Joseph Sriyal Malik Peiris; Benjamin John Cowling
Journal:  Pediatr Infect Dis J       Date:  2014-02       Impact factor: 2.129

4.  A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals.

Authors:  Hartmut J Ehrlich; Julia Singer; Gregory Berezuk; Sandor Fritsch; Gerald Aichinger; Mary Kate Hart; Wael El-Amin; Daniel Portsmouth; Otfried Kistner; P Noel Barrett
Journal:  Clin Infect Dis       Date:  2012-01-19       Impact factor: 9.079

Review 5.  A review of the evidence to support influenza vaccine introduction in countries and areas of WHO's Western Pacific Region.

Authors:  Gina Samaan; Michelle McPherson; Jeffrey Partridge
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.